KR20210072790A - 제조 및 치료를 위한 dnase 효소의 엔지니어링 - Google Patents

제조 및 치료를 위한 dnase 효소의 엔지니어링 Download PDF

Info

Publication number
KR20210072790A
KR20210072790A KR1020217013090A KR20217013090A KR20210072790A KR 20210072790 A KR20210072790 A KR 20210072790A KR 1020217013090 A KR1020217013090 A KR 1020217013090A KR 20217013090 A KR20217013090 A KR 20217013090A KR 20210072790 A KR20210072790 A KR 20210072790A
Authority
KR
South Korea
Prior art keywords
seq
variant
amino acid
linker
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217013090A
Other languages
English (en)
Korean (ko)
Inventor
토비아스 에이. 푹스
알. 압둘 하킴
Original Assignee
뉴트롤리스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴트롤리스 인코포레이티드 filed Critical 뉴트롤리스 인코포레이티드
Publication of KR20210072790A publication Critical patent/KR20210072790A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020217013090A 2018-10-08 2019-10-08 제조 및 치료를 위한 dnase 효소의 엔지니어링 Pending KR20210072790A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862742682P 2018-10-08 2018-10-08
US62/742,682 2018-10-08
US201862775563P 2018-12-05 2018-12-05
US62/775,563 2018-12-05
US201862779104P 2018-12-13 2018-12-13
US62/779,104 2018-12-13
US201962808601P 2019-02-21 2019-02-21
US62/808,601 2019-02-21
US201962846904P 2019-05-13 2019-05-13
US62/846,904 2019-05-13
PCT/US2019/055178 WO2020076817A1 (en) 2018-10-08 2019-10-08 Engineering of dnase enzymes for manufacturing and therapy

Publications (1)

Publication Number Publication Date
KR20210072790A true KR20210072790A (ko) 2021-06-17

Family

ID=70164727

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013090A Pending KR20210072790A (ko) 2018-10-08 2019-10-08 제조 및 치료를 위한 dnase 효소의 엔지니어링

Country Status (12)

Country Link
US (2) US11578314B2 (https=)
EP (1) EP3864147A4 (https=)
JP (2) JP2022504400A (https=)
KR (1) KR20210072790A (https=)
CN (1) CN112996911A (https=)
AU (2) AU2019358915B2 (https=)
BR (1) BR112021006737A2 (https=)
CA (1) CA3115766A1 (https=)
IL (2) IL325846A (https=)
MX (1) MX2021004022A (https=)
SG (1) SG11202103426XA (https=)
WO (1) WO2020076817A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
EP4161645A4 (en) * 2020-06-08 2023-11-01 Yale University COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING COAGULOPATHY AND/OR SEPSIS IN PATIENTS WITH BACTERIAL AND/OR VIRAL INFECTIONS
EP4294824A4 (en) * 2021-02-17 2025-01-01 Neutrolis Inc. DNASE 1-LIKE 2 MANIPULATED FOR PRODUCTION AND USE IN THERAPY
CA3219838A1 (en) * 2021-05-21 2022-11-24 Dmitry Dmitrievich Genkin Immunomodulation of tumor microenvironment
EP4448743A4 (en) * 2021-12-15 2026-01-14 Univ Texas Tech System IMPROVEMENT IN THE SERUM HALF-LIFE OF DNASE1L3
WO2025076525A1 (en) * 2023-10-06 2025-04-10 Neutrolis, Inc. Biomarker and precision therapy for inflammatory disease
WO2026037276A1 (zh) * 2024-08-12 2026-02-19 上海交通大学医学院 一种减少线粒体dna泄露的方法
CN120424194A (zh) * 2025-04-30 2025-08-05 苏州泓迅生物科技股份有限公司 一种重组人源纤连蛋白的制备方法及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6656685B2 (en) * 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US20040138156A1 (en) * 2002-02-26 2004-07-15 Schneider Michael C Therapeutic regulation of deoxyribonuclease-1-like-3 activity
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP2416156B1 (en) 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
US20090305345A1 (en) 2006-10-23 2009-12-10 Medical Research Council Polymerase
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
MX341084B (es) * 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
WO2012106264A2 (en) 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
AU2012222833B2 (en) * 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
ES2666303T3 (es) * 2011-04-29 2018-05-03 University Of Washington Composiciones terapéuticas de nucleasa y métodos
WO2012166611A2 (en) 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
ES2666856T3 (es) * 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
US9867871B2 (en) 2011-12-12 2018-01-16 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107249621A (zh) 2014-09-08 2017-10-13 哥谭生物制药股份有限公司 用于治疗肺结节病的粘液溶解剂
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3273238A1 (en) 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
CA3036926C (en) 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP3570667B1 (en) * 2017-01-20 2022-11-16 Neutrolis Inc. Animal model for drug development
DK3668972T3 (da) * 2017-08-18 2025-01-13 Neutrolis Inc Konstruerede dnase-enzymer og anvendelse i terapi
US10988746B2 (en) * 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
EA202190940A1 (ru) * 2019-05-13 2021-10-15 Ньютролис Инк. РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
EP4294824A4 (en) * 2021-02-17 2025-01-01 Neutrolis Inc. DNASE 1-LIKE 2 MANIPULATED FOR PRODUCTION AND USE IN THERAPY

Also Published As

Publication number Publication date
SG11202103426XA (en) 2021-05-28
US11578314B2 (en) 2023-02-14
EP3864147A4 (en) 2022-07-06
US12565642B2 (en) 2026-03-03
WO2020076817A1 (en) 2020-04-16
US20240191218A1 (en) 2024-06-13
IL325846A (en) 2026-03-01
IL282058B1 (en) 2026-02-01
EP3864147A1 (en) 2021-08-18
AU2019358915B2 (en) 2025-09-18
CA3115766A1 (en) 2020-04-16
JP7818850B2 (ja) 2026-02-24
MX2021004022A (es) 2021-09-10
AU2025283522A1 (en) 2026-01-15
US20220162575A1 (en) 2022-05-26
JP2024160327A (ja) 2024-11-13
AU2025283522B2 (en) 2026-03-19
AU2019358915A1 (en) 2021-05-20
JP2022504400A (ja) 2022-01-13
IL282058A (en) 2021-05-31
BR112021006737A2 (pt) 2021-07-13
CN112996911A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
US12565642B2 (en) Engineered DNASE enzymes for thrombosis therapy
US11840712B2 (en) Engineering of DNASE enzymes for manufacturing and therapy
US20080227691A1 (en) Blood Coagulation FVIII Analogues
KR20090110936A (ko) 카잘-형 세린 프로테아제 억제제의 치료학적 적용
US20240374643A1 (en) Dnase1-like 3 and its use in therapy
CZ305602B6 (cs) Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu
KR102682612B1 (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
JP2738428B2 (ja) トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
US20240401015A1 (en) Dnase enzymes engineered for improved stability
US20250129347A1 (en) Engineered human extracellular dnase enzymes
EA046216B1 (ru) РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
KR20250109224A (ko) 개선된 발현 및 치료법에 사용을 위해 조작된 DNase 1 유사 3
EA052450B1 (ru) РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
AU2008214916B2 (en) Therapeutic application of Kazal-type serine protease inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000